The Current State of Unapproved Cannabidiol Product Use in Children

儿童使用未经批准的大麻二酚产品的现状

阅读:1

Abstract

Cannabidiol (CBD) is a naturally occurring cannabinoid isolated from Cannabis sativa. CBD has therapeutic benefit for the treatment of seizures associated with various epilepsy syndromes in children; however, data are lacking related to the use of CBD for other indications in pediatric patients. Despite this lack of clinical data, the use of CBD products as a complementary treatment for various conditions in children continues to increase. Thus, it is imperative that those involved in the care of children and adolescents are well informed with current information related to CBD use in pediatrics. This review will address the pharmacology of CBD, legal and regulatory factors, usage patterns, current efficacy data, and safety concerns related to the use of CBD in children and adolescents. Recommendations for clinicians, public health officials, and researchers are also provided to effectively manage the use of unapproved CBD products in the pediatric population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。